At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed CD20+ B-cell lymphoma with failure of at least one prior standard systemic therapy
- ✓Evidence of persistent lymphoma by physical exam, imaging, bone marrow, flow cytometry, or PCR
- ✓Creatinine <2.0 mg/dL
- ✓Bilirubin <1.5 mg/dL
- ✕Systemic anti-lymphoma therapy within previous 30 days
- ✕Progressive disease within 3 months of prior Bexxar or Zevalin
- ✕Central nervous system lymphoma
- ✕ECOG performance score >2
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating rituximab, cyclosporine, and 6 other interventions for B-cell Chronic Lymphocytic Leukemia and 16 related conditions. Completed, enrolled 42 participants across 1 site.
Detailed Summary
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells. Giving monoclonal antibodies, low doses of chemotherapy, such as fludarabine phosphate, and low dose total-body radiation therapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells and also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine or mycophenolate mofetil after the transplant may stop this from happening
Study Details
Timeline
Interventions
Given IV
Given orally
Given IV
Given orally
Given IV
Undergo transplantation
Undergo transplantation
Undergo TBI